# US 2026/0062713 A1 · Adeno-associated virus delivery of cln3 polynucleotide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062713 A1
- Document ID: US20260062713A1
- Status: Published application
- Kind: A1
- Application number: 19/289,974
- Filed: 2025-08-04
- Published: 2026-03-05
- Earliest claimed: 2019-02-04
- Assignees: Research Institute At Nationwide Children's Hospital; Ohio State Innovation Foundation
- Applicants: Research Institute At Nationwide Children's Hospital; Ohio State Innovation Foundation
- Inventors: Kathrin Meyer; Brian K. Kaspar; Kevin Foust
- Web page: https://patentgrep.com/patent/US20260062713A1

## CPC

- C12N 15/86: Viral vectors
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/47: from mammals
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of a ceroid lipofuscinosis neuronal 3 (CLN3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for CLN3 gene therapy of the neuronal ceroid lipofuscinosis or CLN3-Batten Discase.

## Claims

### Claim at position 1

1-71. (canceled)

### Claim 72

A DNA plasmid comprising a recombinant adeno-associate virus (rAAV) genome, wherein the rAAV genome comprises a nucleotide sequence having at 90% sequence similarity to the nucleic acid sequence of SEQ ID NO: 4

### Claim 73 (depends on 72)

The DNA plasmid of claim 72, wherein the DNA plasmid lacks AAV rep and cap genes.

### Claim 74 (depends on 72)

The DNA plasmid of claim 72, further comprising a selectable marker.

### Claim 75 (depends on 72)

The DNA plasmid of claim 72, wherein the rAAV genome is a self-complementary genome (scAAV).

### Claim 76

The DNA plasmid of clam 72, wherein the rAAV genome is a single-stranded genome.

### Claim 77 (depends on 72)

A cell comprising the DNA plasmid of claim 72.

### Claim 78 (depends on 77)

The cell of claim 77, wherein the cell is a Hela cell, 293 cell, PerC.6 cell, MRC-5 cell, WI-38 cell, Vero cell, or FRhL-2 cell.

### Claim 79 (depends on 72)

A method of making a recombinant adeno-associated virus (rAAV) for the treatment of CLN3-Batten Disease, comprising:
transferring the DNA plasmid of claim 72 into a cell;
producing rAAV particles encapsidating the DNA plasmid in the cell; and
isolating the rAAV particles from the cell.

### Claim 80 (depends on 79)

The method of claim 79, wherein the cell is a Hela cell, 293 cell, PerC.6 cell, MRC-5 cell, WI-38 cell, Vero cell, or FRhL-2 cell.

### Claim 81 (depends on 79)

The method of claim 79, further comprising a step of transferring AAV helper and AAV rep/cap plasmids into the cell.

### Claim 82 (depends on 81)

The method of claim 81, wherein the rep/cap plasmid encodes for AAV9 capsid proteins.

### Claim 83 (depends on 77)

An rAAV particle produced using the cell of claim 77.

### Claim 84 (depends on 79)

An rAAV particle produced using the method of claim 79.
